What is the purpose of TransDigm’s Director Share Plan mentioned in this filing?

The Director Share Plan allows TransDigm to pay semi-annual director fees in stock instead of cash. In this case, Jane M. Cronin received 30 common shares based on fair market value, aligning director compensation with company equity performance.

TransDigm director receives stock fee grant

TransDigm Group director Jane M. Cronin received a stock grant as board compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TransDigm Group director Jane M. Cronin received a stock grant as board compensation. She acquired 30 shares of TransDigm common stock on March 20, 2026 at a fair market value of $1,214.66 per share, issued in lieu of her semi-annual director fee under the Director Share Plan.

Following this grant, Cronin directly holds 699.62 shares of TransDigm common stock. This is a routine equity compensation award rather than an open‑market share purchase or sale.

Insider Trade Summary

Grant/Award: 30 shares

Grant/Award 1 txn

Insider CRONIN JANE M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30	$1,214.66	$36K

Holdings After Transaction: Common Stock — 699.62 shares (Direct)

Footnotes (1)

F1. Receipt of stock in lieu of payment of semi-annual director fee, based on fair market value in accordance with the Director Share Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TransDigm (TDG) director Jane M. Cronin report in this Form 4?

Jane M. Cronin reported receiving 30 shares of TransDigm common stock. The shares were granted as part of her semi-annual director fee, paid in stock at fair market value under the company’s Director Share Plan.

Was the TransDigm (TDG) director transaction an open-market buy or a stock grant?

The transaction was a stock grant, not an open-market purchase. Cronin received 30 shares of common stock as compensation, issued in lieu of cash for her semi-annual director fee under the Director Share Plan.

At what price was the TransDigm (TDG) director stock grant valued?

The 30-share grant to director Jane M. Cronin was valued at $1,214.66 per share. This price reflects the fair market value used to convert her semi-annual director fee into TransDigm common stock.

How many TransDigm (TDG) shares does Jane M. Cronin hold after this grant?

After receiving the 30-share grant, Jane M. Cronin directly holds 699.62 shares of TransDigm common stock. This total reflects her updated direct ownership position immediately following the reported compensation award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/23/2026 - 04:27 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CRONIN JANE M.

(Last)

(First)

(Middle)

1350 EUCLID AVE

SUITE 1600

(Street)

CLEVELAND

OHIO

44115

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransDigm Group INC [ TDG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2026		A		30⁽¹⁾	A	$1,214.66	699.62	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Receipt of stock in lieu of payment of semi-annual director fee, based on fair market value in accordance with the Director Share Plan.

	/s/ Rachel L. Quinlan as attorney in fact for Jane Cronin	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR